DK2583680T1 - Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV - Google Patents
Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV Download PDFInfo
- Publication number
- DK2583680T1 DK2583680T1 DK12189195.6T DK12189195T DK2583680T1 DK 2583680 T1 DK2583680 T1 DK 2583680T1 DK 12189195 T DK12189195 T DK 12189195T DK 2583680 T1 DK2583680 T1 DK 2583680T1
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- combination
- compound
- psi
- hcv genotype
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (17)
1. Kombination af mindst to direktevirkende antivirale midler (DAA) til anvendelse ved behandling af HTV, hvor nævnte behandling ikke indbefatter administrering af hverken interferon eller ribavirin, og nævnte behandling varer i 8, 9, 10, 11 eller 12 uger.
2. Kombination ifølge krav 1, hvor nævnte behandling varer i 12 uger.
3. Kombination ifølge krav 2, hvor nævnte mindst to DAA omfatter BMS-790052 og BMS-650032.
4. Kombination ifølge krav 3, hvor nævnte behandling er til behandling af en behandlings-naiv patient, som er inficeret med HCV-genotype 1.
5. Kombination ifølge krav 2, hvor nævnte mindst to DAA omfatter PSI-7977 og TMC-435.
6. Kombination ifølge krav 5, hvor nævnte behandling er til behandling af en behandlings-naiv patient, som er inficeret med HCV-genotype 1.
7. Kombination ifølge krav 2, hvor nævnte mindst to DAA omfatter PSI-7977 og daclatasvir.
8. Kombination ifølge krav 7, hvor nævnte behandling er til en behandlingsnaiv patient, som er inficeret med HCV-genotype 1.
9. Kombination ifølge krav 2, hvor nævnte mindst to DAA omfatter PSI-7977 og GS-5885.
10. Kombination ifølge krav 9, hvor nævnte behandling er til en behandlingsnaiv patient, som er inficeret med HCV-genotype 1.
11. Kombination ifølge krav 2, hvor nævnte mindst to DAA omfatter: forbindelse 1 eller et farmaceutisk acceptabelt salt heraf, og forbindelse 4 eller et farmaceutisk acceptabelt salt heraf, hvor forbindelse 1 eller saltet heraf administreres samtidigt med ritonavir.
12. Kombination ifølge krav 11, hvor nævnte behandling er til en behandlingsnaiv patient, som er inficeret med HCV-genotype 1.
13. Kombination ifølge krav 2, hvor nævnte mindst to DAA omfatter: forbindelse 1 eller et farmaceutisk acceptabelt salt heraf, forbindelse 2 eller et farmaceutisk acceptabelt salt heraf, og forbindelse 4 eller et farmaceutisk acceptabelt salt heraf, hvor forbindelse 1 eller saltet heraf administreres samtidig med ritonavir.
14. Kombination ifølge krav 13, hvor nævnte behandling er for en behandlingsnaiv patient, som er inficeret med HCV-genotype 1.
15. Kombination ifølge krav 13, hvor nævnte behandling er til en interferon-non-responder, som er inficeret med HCV-genotype 1.
16. PSI-7977 til anvendelse ved behandling af HCV, hvor nævnte behandling ikke indbefatter administrering af hverken inteferon eller ribavirin, og nævnte behandling varer i 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 201,21,22, 23 eller 24 uger.
17. PSI-799 ifølge krav 16, hvor nævnte behandling varer i 12 uger.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550360P | 2011-10-21 | 2011-10-21 | |
US201161562176P | 2011-11-21 | 2011-11-21 | |
US201261587197P | 2012-01-17 | 2012-01-17 | |
US201261600468P | 2012-02-17 | 2012-02-17 | |
US201261619883P | 2012-04-03 | 2012-04-03 | |
US201261656253P | 2012-06-06 | 2012-06-06 | |
US201261711793P | 2012-10-10 | 2012-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2583680T1 true DK2583680T1 (da) | 2015-01-19 |
Family
ID=47143548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12189195.6T DK2583680T1 (da) | 2011-10-21 | 2012-10-19 | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
Country Status (27)
Country | Link |
---|---|
US (2) | US8809265B2 (da) |
EP (1) | EP2583680A3 (da) |
JP (2) | JP5677646B2 (da) |
CN (2) | CN104023726A (da) |
AR (1) | AR088408A1 (da) |
AU (1) | AU2013201532B2 (da) |
BR (1) | BR112014005617A2 (da) |
CA (1) | CA2811250C (da) |
CH (1) | CH707030B1 (da) |
CL (2) | CL2014000778A1 (da) |
DE (6) | DE112012002813T5 (da) |
DK (1) | DK2583680T1 (da) |
DO (1) | DOP2014000067A (da) |
EA (1) | EA201490836A1 (da) |
ES (1) | ES2527544T1 (da) |
GB (4) | GB2515942A (da) |
HK (2) | HK1199817A1 (da) |
IL (1) | IL230862A0 (da) |
MX (1) | MX2014004729A (da) |
PH (1) | PH12014502847A1 (da) |
PT (2) | PT107925A (da) |
SE (2) | SE1450131A1 (da) |
SG (1) | SG2014011670A (da) |
TW (2) | TWI532485B (da) |
UY (1) | UY34401A (da) |
WO (1) | WO2013059638A1 (da) |
ZA (1) | ZA201406352B (da) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
MX354958B (es) | 2011-09-16 | 2018-03-27 | Gilead Pharmasset Llc | Metodos para el tratamiento de vhc. |
US8492386B2 (en) * | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
UY34401A (es) * | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2015003500A (es) * | 2012-09-18 | 2015-06-22 | Abbvie Inc | Metodos para tratar hepatitis c. |
EP2897611B1 (en) * | 2012-09-18 | 2019-07-24 | AbbVie Inc. | Methods for treating hepatitis c |
EP2908808A1 (en) * | 2012-10-18 | 2015-08-26 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
PL2950786T3 (pl) | 2013-01-31 | 2020-05-18 | Gilead Pharmasset Llc | Formulacja skojarzona dwóch związków przeciwwirusowych |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
KR20210013344A (ko) | 2013-03-14 | 2021-02-03 | 애브비 인코포레이티드 | C형 간염 치료용 2가지 항바이러스제의 병용물 |
EA030482B1 (ru) | 2013-03-14 | 2018-08-31 | Эббви Инк. | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN105451736A (zh) * | 2013-07-02 | 2016-03-30 | 艾伯维公司 | 用于治疗hcv的方法 |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
EP3016651A1 (en) * | 2013-07-02 | 2016-05-11 | AbbVie Inc. | Methods for treating hcv |
EP3021845A1 (en) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
US20150141351A1 (en) * | 2013-11-18 | 2015-05-21 | AbbVie Deutschland GmbH & Co. KG | Solid Pharmaceutical Compositions |
WO2015095572A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
CN106413711A (zh) | 2014-04-02 | 2017-02-15 | 艾伯维公司 | 治疗hcv的方法 |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
WO2016089814A1 (en) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Deuterated analogues of daclatasvir |
US20180338993A1 (en) * | 2014-12-04 | 2018-11-29 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US10654909B2 (en) | 2014-12-04 | 2020-05-19 | Novartis Ag | Soluble alpha klotho and serum albumin fusion protein |
CN104546780A (zh) * | 2014-12-12 | 2015-04-29 | 安徽一灵药业有限公司 | 一种达卡他韦薄膜包衣片制剂及其制备方法 |
HUE054068T2 (hu) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
US20180177778A1 (en) * | 2015-06-29 | 2018-06-28 | Abbvie Inc. | Methods for Treating HCV |
EP3319604A1 (en) | 2015-07-08 | 2018-05-16 | AbbVie Inc. | Methods for treating hcv |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
JP2018131439A (ja) | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Hcvを処置する方法 |
CA2981993A1 (en) | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
CA3078939A1 (en) | 2017-10-12 | 2019-04-18 | Abbvie Inc. | Methods for treating hcv |
Family Cites Families (403)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
WO1994001125A1 (en) | 1992-07-13 | 1994-01-20 | Sherman Kenneth E | Composition and method of treating hepatitis b |
US6107027A (en) | 1994-12-14 | 2000-08-22 | University Of Washington | Ribozymes for treating hepatitis C |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
GB9605293D0 (en) | 1996-03-13 | 1996-05-15 | Glaxo Group Ltd | Medicaments |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
AU5157998A (en) | 1996-11-01 | 1998-05-29 | Thomas Najarian | Methods and compositions for treatment of hepatitis c infection |
IL119833A (en) | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
US6010890A (en) | 1997-04-29 | 2000-01-04 | New York Blood Center, Inc. | Method for viral inactivation and compositions for use in same |
US6103706A (en) | 1997-04-29 | 2000-08-15 | New York Blood Center, Inc. | Methods for treating viral infections |
US6143752A (en) | 1997-08-01 | 2000-11-07 | Oren; Ran | Method for preventing or arresting liver damage in humans |
EP0903148B1 (en) | 1997-09-21 | 2001-10-10 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
US6455051B1 (en) | 1997-10-13 | 2002-09-24 | Otsuka Pharmaceutical Co., Ltd. | Ameliorant for hepatitis C therapeutic effect and application thereof |
FR2771637B1 (fr) | 1997-12-01 | 2003-10-24 | Hutchinson | Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales |
JP2001525367A (ja) | 1997-12-11 | 2001-12-11 | ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード | 膜関連ウイルス複製の阻害 |
WO1999030721A1 (en) | 1997-12-17 | 1999-06-24 | Cornell Research Foundation, Inc. | Cyclooxygenase-2 inhibition |
US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
US6475985B1 (en) | 1998-03-27 | 2002-11-05 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
JP2000007578A (ja) | 1998-06-24 | 2000-01-11 | Hiroaki Okushin | C型肝炎ウイルスの陰性化のための投薬システム |
USRE40987E1 (en) | 1998-07-01 | 2009-11-17 | Debiopharm S.A. | Cyclosporin with improved activity profile |
RU2158604C2 (ru) | 1998-07-03 | 2000-11-10 | Толоконская Наталья Петровна | Способ лечения вирусного гепатита c |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
BR9915546A (pt) | 1998-10-16 | 2001-08-14 | Schering Corp | Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica |
US20080275005A1 (en) | 1998-11-25 | 2008-11-06 | Murphy Michael P | Mitochondrially targeted antioxidants |
US6824768B2 (en) | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
CA2354536A1 (en) | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
AR022116A1 (es) | 1998-12-18 | 2002-09-04 | Schering Corp | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa |
JP2000212099A (ja) | 1999-01-19 | 2000-08-02 | Mochida Pharmaceut Co Ltd | ウイルス性肝炎治療剤 |
KR100630520B1 (ko) | 1999-02-13 | 2006-09-29 | 퓨어펄스 테크놀러지즈 인코포레이티드 | 광역-스펙트럼 펄스광을 사용하는 병원체의 불활성화 방법 |
MXPA00012330A (es) | 1999-04-12 | 2004-12-03 | Univ Madras | Formulacion farmaceutica util para el tratamiento de hepatitis b, hepatitis c y otras infecciones virales del higado, y un procedimiento para su preparacion. |
US6849254B1 (en) | 1999-04-19 | 2005-02-01 | Schering Corporation | HCV combination therapy |
WO2002038105A2 (en) | 2000-11-08 | 2002-05-16 | Slil Biomedical Corporation | Novel polyamine analog-amino acid conjugates useful as anticancer agents |
DE60042073D1 (de) | 1999-07-22 | 2009-06-04 | Celmed Oncology Usa Inc | Enzym katalisierte therapeutische aktivierung |
PE20010490A1 (es) | 1999-08-13 | 2001-04-27 | Hoffmann La Roche | Micofenolato mofetil en asociacion con peg-ifn-alfa |
US20050245502A1 (en) | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
KR100392292B1 (ko) | 2000-01-07 | 2003-07-22 | 주식회사 펩트론 | 5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물 |
US6727267B2 (en) | 2000-04-05 | 2004-04-27 | Tularik Inc. | NS5B HVC polymerase inhibitors |
CA2389691A1 (en) | 2000-04-07 | 2001-10-18 | Shionogi & Co., Ltd. | A pre-incubation method for an assay of an inhibitor to an hcv rna-dependent rna polymerase |
EP1332231B1 (en) | 2000-04-18 | 2008-08-13 | Virco Bvba | Methods for measuring drug resistance |
US6415797B1 (en) | 2000-07-07 | 2002-07-09 | First Circle Medical, Inc. | Treatment of human herpesviruses using hyperthermia |
DE60141608D1 (de) | 2000-07-21 | 2010-04-29 | Dendreon Corp | Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
WO2002010743A1 (en) | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
PT1326632E (pt) | 2000-10-12 | 2007-01-31 | Viromics Gmbh | Tratamento para o tratamento de infecções por vírus da hepatite |
EP1363703A4 (en) | 2000-10-13 | 2006-06-07 | Univ Monash | PREVENTION OF DISEASES BY REACTIVATION OF THYMUS |
CN1516599A (zh) | 2000-10-18 | 2004-07-28 | ���鹫˾ | 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法 |
FR2815543B1 (fr) | 2000-10-19 | 2003-10-24 | Sedat | Seringue d'auto-injection d'un melange extemporane |
ATE405282T1 (de) | 2000-10-20 | 2008-09-15 | Genetics Inst | Verwendung von il-13 inhibitoren zur behandlung von tumoren |
AU2002245081A1 (en) | 2000-12-06 | 2002-07-16 | The Trustees Of The University Of Pennsylvania | Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
EP1707571B1 (en) | 2001-01-22 | 2011-09-28 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
US6673775B2 (en) | 2001-04-18 | 2004-01-06 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
WO2002089731A2 (en) | 2001-05-03 | 2002-11-14 | Stanford University | Agents for treatment of hcv and methods of use |
US6833351B2 (en) | 2001-05-21 | 2004-12-21 | Douglas T. Dieterich | Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha |
CN1522159A (zh) | 2001-06-29 | 2004-08-18 | 马克西根公司 | 干扰素配制品 |
US20030138403A1 (en) | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
US20040241138A1 (en) | 2001-07-20 | 2004-12-02 | Hsu Henry H. | Methods of treating liver fibrosis |
WO2003024461A1 (en) | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
EP1435997A4 (en) | 2001-09-28 | 2006-03-01 | Intermune Inc | TECHNIQUE FOR TREATING HEPATITIS C VIRUS INFECTION FOR PATIENTS WHOSE TREATMENT FAILED |
PL369129A1 (en) | 2001-09-28 | 2005-04-18 | Intermune, Inc. | Method for treating hepatitis c virus infection in treatment failure patients |
US20050063949A1 (en) | 2001-10-05 | 2005-03-24 | Gary Visor | Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
WO2003037908A1 (en) | 2001-10-31 | 2003-05-08 | Ribapharm Inc. | Antiviral combination therapy and compositions |
AR037131A1 (es) | 2001-10-31 | 2004-10-20 | Schering Corp | Formulaciones de jarabe de ribavirina |
JP2005536982A (ja) | 2001-11-07 | 2005-12-08 | 麒麟麦酒株式会社 | インビトロにおけるt細胞増幅および増幅されたt細胞集団 |
AUPR879601A0 (en) | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
WO2003049760A1 (en) | 2001-12-07 | 2003-06-19 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
US6936629B2 (en) | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
US6906190B2 (en) | 2002-01-04 | 2005-06-14 | Ribapharm Inc. | Inhibitors for de novo-RNA polymerases and methods of identifying targets for same |
RU2212248C1 (ru) | 2002-01-21 | 2003-09-20 | Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова | Способ лечения больных хроническим вирусным гепатитом c |
JP2005522457A (ja) | 2002-02-26 | 2005-07-28 | ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート | 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害 |
CA2383243A1 (en) | 2002-04-23 | 2003-10-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for inhibiting fibrogenesis |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20040034206A1 (en) | 2002-05-31 | 2004-02-19 | Schering Corporation | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors |
TWI334785B (en) | 2002-06-03 | 2010-12-21 | Serono Lab | Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
ITMI20021860A1 (it) | 2002-08-28 | 2004-02-29 | Scalia Antonio Cassar | Impiego dei triptani come agenti antivirali. |
US20060223145A1 (en) | 2002-11-01 | 2006-10-05 | Lohray Braj B | Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris |
AU2003287666A1 (en) | 2002-11-13 | 2004-06-03 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
WO2004047673A2 (en) | 2002-11-21 | 2004-06-10 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
EP1596846A2 (en) | 2003-02-18 | 2005-11-23 | Pfizer Inc. | Inhibitors of hepatitis c virus, compositions and treatments using the same |
US20070077225A1 (en) | 2003-02-28 | 2007-04-05 | Blatt Lawrence M | Continuous delivery methods for treating hepatitis virus infection |
WO2005016288A2 (en) | 2003-02-28 | 2005-02-24 | Intermune, Inc. | Methods and compositions for treatment of viral diseases |
WO2004078194A1 (en) | 2003-02-28 | 2004-09-16 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
TWI269656B (en) | 2003-03-05 | 2007-01-01 | Original Image Co Ltd | Therapeutical composition for hepatitis C |
UA64191A (en) | 2003-03-14 | 2004-02-16 | Yevhenii Mykhailovych Neiko | Method for treating chronic hepatitises of various etiology |
US20040198840A1 (en) | 2003-04-02 | 2004-10-07 | Deloach Reuben Edwin | Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation |
WO2004094452A2 (en) | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
US20040258663A1 (en) | 2003-05-08 | 2004-12-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon alpha |
US20050009877A1 (en) | 2003-05-15 | 2005-01-13 | Henry Lu | Methods of identifying HCV NS5B polymerase inhibitors and their uses |
EA009295B1 (ru) | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения в качестве ингибиторов вируса гепатита с |
ES2726998T3 (es) | 2003-05-30 | 2019-10-11 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
US20050187170A1 (en) | 2003-06-16 | 2005-08-25 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors |
JP2007537131A (ja) | 2003-06-20 | 2007-12-20 | ヴァイラル・ジェノミックス・インコーポレーテッド | 抗ウイルス組成物および同一物を使用する方法 |
CA2532084A1 (en) | 2003-07-11 | 2005-02-03 | Oregon Health And Science University | Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences |
MD2549G2 (ro) | 2003-07-18 | 2005-08-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Metodă de tratament a hepatitei virale cronice C. |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
WO2005018330A1 (en) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
NZ545536A (en) | 2003-09-05 | 2010-04-30 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C |
US20070110714A1 (en) | 2003-09-08 | 2007-05-17 | Norio Hayashi | Medicinal composition for treatment of chronic hepatitis c |
AR045870A1 (es) | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
WO2005038056A1 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Combination therapy for the treatment of viral diseases |
EA011857B8 (ru) | 2003-10-14 | 2012-08-30 | Интермьюн, Инк. | Макроциклические карбоновые кислоты и ацилсульфонамиды в качестве ингибиторов репликации вируса гепатита с |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US20050085528A1 (en) | 2003-10-17 | 2005-04-21 | Pfizer Inc. | Parmaceutical |
JP4931593B2 (ja) | 2003-10-24 | 2012-05-16 | イミュネイド ピーティーワイ リミテッド | 治療の方法 |
US8187874B2 (en) | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
PL1677827T3 (pl) | 2003-10-27 | 2009-06-30 | Vertex Pharma | Połączenia do leczenia HCV |
UA68233A (en) | 2003-11-25 | 2004-07-15 | Univ Zaporizhia State Medical | Method for treating chronic hepatitis c |
US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
US20050222198A1 (en) | 2003-12-22 | 2005-10-06 | K.U. Leuven Research & Development, Gerhard Puerstinger And Gilead Sciences, Inc. | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
WO2005067454A2 (en) | 2003-12-23 | 2005-07-28 | Valeant Pharmaceuticals North America | Combination therapy for treating hepatitis c virus infection |
WO2005062949A2 (en) | 2003-12-23 | 2005-07-14 | Intermune, Inc. | Method for treating hepatitis virus infection |
WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
DE10361944A1 (de) | 2003-12-31 | 2005-07-28 | Viromics Gmbh | Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung |
US20080234182A1 (en) | 2007-03-22 | 2008-09-25 | Innovative Biologics, Inc. | Blockers of pore-forming virulence factors and their use as anti-infectives |
EP1718315A4 (en) | 2004-02-06 | 2008-08-13 | Univ Monash | HIGH-DOSE USE AND SHORT INTERVAL OF SULFATE POLYSACCHARIDES IN THE TREATMENT OF INFECTIONS |
US7205330B2 (en) | 2004-02-27 | 2007-04-17 | Schering Corporation | Inhibitors of hepatitis C virus NS3 protease |
EP1755615B1 (en) | 2004-04-22 | 2013-11-27 | Howard J. Smith & Associates Pty Ltd | Supportive treatment of liver disease |
PL1747023T5 (pl) | 2004-05-04 | 2017-05-31 | Univ Leland Stanford Junior | Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych |
PE20060309A1 (es) | 2004-05-06 | 2006-04-13 | Schering Corp | (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l |
CA2565658A1 (en) | 2004-05-06 | 2005-11-17 | Conjuchem Biotechnologies Inc. | Compounds for specific viral target |
WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
WO2005116054A1 (en) | 2004-05-25 | 2005-12-08 | Boehringer Ingelheim International, Gmbh | Process for preparing acyclic hcv protease inhibitors |
BRPI0511900A (pt) | 2004-06-08 | 2008-01-22 | Vertex Pharma | composições farmacêuticas |
DE602005026294D1 (de) | 2004-07-14 | 2011-03-24 | Novartis Ag | Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
EP1627641A1 (en) | 2004-08-04 | 2006-02-22 | Victor Eluwa | Pharmaceutical compositions comprising metal oxides and uses thereof |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
CA2581930A1 (en) | 2004-09-27 | 2006-04-06 | Jane Trepel | Modulating mxa expression |
MX2007003812A (es) | 2004-10-01 | 2007-05-24 | Vertex Pharma | Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc). |
WO2006038088A1 (en) | 2004-10-01 | 2006-04-13 | Debiopharm Sa | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin |
US7723310B2 (en) | 2004-10-18 | 2010-05-25 | Three Rivers Pharmaceuticals, Llc | Large dose ribavirin formulations |
US20060228333A1 (en) | 2004-10-20 | 2006-10-12 | Kye-Hyung Paik | Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues |
WO2006043153A2 (en) | 2004-10-20 | 2006-04-27 | Michel Xilinas | Use of zinc and copper chelators for the treatment of viral diseases |
MX2007004979A (es) | 2004-10-26 | 2007-06-14 | Angeletti P Ist Richerche Bio | Derivados de indol tetraciclicos como agentes antiviricos. |
TW201424733A (zh) | 2004-10-29 | 2014-07-01 | Vertex Pharma | 劑量型式 |
US7592315B2 (en) | 2004-11-02 | 2009-09-22 | Schering Corporation | Peptide viral entry inhibitors |
US20060105063A1 (en) | 2004-11-18 | 2006-05-18 | Kent Hann | Synergic combination of compositions containing aloe vera isolates and their therapeutic application |
US8399428B2 (en) | 2004-12-09 | 2013-03-19 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
TW200633718A (en) | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
EP1674104A1 (en) | 2004-12-24 | 2006-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV |
EP1679065A1 (en) | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
KR20070104355A (ko) | 2005-01-17 | 2007-10-25 | 제리니 아게 | C5a 수용체 안타고니스트 |
EP2361630A1 (en) | 2005-02-03 | 2011-08-31 | Intarcia Therapeutics, Inc | Implantable drug delivery device comprising particles and an osmotic pump |
EP1853317A2 (en) | 2005-02-09 | 2007-11-14 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
US20060198787A1 (en) | 2005-02-18 | 2006-09-07 | Larry Blatt | Biomarkers for predicting liver fibrosis treatment efficacy |
WO2006091610A2 (en) | 2005-02-23 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Inhibitors of enveloped virus infectivity |
US20090156545A1 (en) | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
US20060229293A1 (en) | 2005-04-06 | 2006-10-12 | Addiction Research Institute, Inc. | Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C |
EP1865967A4 (en) | 2005-04-08 | 2011-02-09 | Chimerix Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES |
WO2006113431A2 (en) | 2005-04-13 | 2006-10-26 | University Of Massachusetts | Dual functional oligonucleotides for use as anti-viral agents |
US20060241144A1 (en) | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
NZ563909A (en) | 2005-05-13 | 2011-10-28 | Virochem Pharma Inc | Thiophene derivatives and their use for the treatment or prevention of flavivirus infections |
EP1881828A4 (en) | 2005-05-20 | 2009-06-03 | Valeant Res & Dev | TREATMENT OF HEPATITIS C (HCV) USING SUB-THERAPEUTIC DOSES OF RIBAVIRIN |
WO2006127482A1 (en) | 2005-05-20 | 2006-11-30 | Bioenvision, Inc. | Methylene blue therapy of viral disease |
CA2609613A1 (en) | 2005-05-26 | 2006-11-30 | Schering Corporation | Interferon-igg fusion |
MX2007015085A (es) | 2005-05-31 | 2008-01-17 | Novartis Ag | Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis. |
US7793040B2 (en) | 2005-06-01 | 2010-09-07 | Microsoft Corporation | Content addressable memory architecture |
US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
WO2006130626A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
BRPI0610737A2 (pt) | 2005-06-02 | 2010-07-20 | Schering Corp | formulações farmacêuticas e métodos de tratamento usando as mesmas |
US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
US20070232527A1 (en) | 2005-06-02 | 2007-10-04 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
WO2006130687A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor |
WO2006130553A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
US20070207949A1 (en) | 2005-06-02 | 2007-09-06 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
WO2006130554A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
US20060276406A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
WO2006130688A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Compounds for inhibiting cathepsin activity |
WO2006133092A1 (en) | 2005-06-07 | 2006-12-14 | Yale University | Methods of treating cancer and other conditions or disease states using lfmau and ldt |
RU2293572C1 (ru) | 2005-07-18 | 2007-02-20 | Гюнтер Хаазе | Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью |
AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
ES2401661T3 (es) | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
AU2006280312A1 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DE102005038768A1 (de) | 2005-08-16 | 2007-02-22 | Toximed Gmbh | Pharmazeutischer Wirkstoff gegen Borreliose |
ES2449268T3 (es) | 2005-08-19 | 2014-03-19 | Vertex Pharmaceuticals Inc. | Procesos |
US8193328B2 (en) | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
US7531164B2 (en) | 2005-10-21 | 2009-05-12 | Duke University | Preventing bacterial or viral infectivity and composition containing infection preventing additive |
IE20050723A1 (en) | 2005-10-28 | 2007-05-30 | Patrick T Prendergast | Anti-mineralocorticoid therapy of infection |
WO2007056016A2 (en) | 2005-11-02 | 2007-05-18 | Kemia, Inc. | Bisamide cytokine inhibitors |
RU2306134C2 (ru) | 2005-11-07 | 2007-09-20 | Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" | Способ базисного лечения хронического вирусного гепатита c |
EP1951748B1 (en) | 2005-11-11 | 2013-07-24 | Vertex Pharmaceuticals, Inc. | Hepatitis c virus variants |
WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
RU2326115C2 (ru) | 2005-11-21 | 2008-06-10 | Ефаг АО | Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения |
AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
EP1968607B1 (en) | 2005-12-02 | 2014-01-15 | Nabil Habib Lab | Treatment of cancer and other diseases |
EP1957510A1 (en) | 2005-12-09 | 2008-08-20 | F.Hoffmann-La Roche Ag | Antiviral nucleosides |
WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
RU2306934C1 (ru) | 2005-12-28 | 2007-09-27 | ГОУ ВПО Омская Государственная Медицинская Академия | Способ лечения больных хроническим вирусным гепатитом c |
NZ569507A (en) | 2006-01-09 | 2011-11-25 | Romark Lab Lc | Viral hepatitis treatment using nitazoxanide or tizoxanide |
MD20060037A (ro) | 2006-01-24 | 2007-07-31 | Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова | Metodă de tratament al hepatitei virale acute C |
WO2007092645A2 (en) | 2006-02-09 | 2007-08-16 | Schering Corporation | Novel hcv inhibitor combinations and methods |
US20070274951A1 (en) | 2006-02-09 | 2007-11-29 | Xiao Tong | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
TWI428125B (zh) | 2006-03-20 | 2014-03-01 | Vertex Pharma | 對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物 |
JP2009530415A (ja) | 2006-03-20 | 2009-08-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
MX2008012225A (es) | 2006-03-23 | 2008-12-03 | Schering Corp | Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas. |
EP2016100B1 (en) | 2006-05-04 | 2014-07-09 | The Rockefeller University | Hcv coreceptor and methods of use thereof |
WO2008060695A2 (en) | 2006-05-22 | 2008-05-22 | The Trustees Of The University Of Pennsylvania | Antiviral inhibition of casein kinase ii |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
EP2037929A4 (en) | 2006-06-02 | 2010-02-17 | Univ San Diego State Res Found | COMPOSITIONS AND METHODS FOR REDUCING HYPERLIPIDEMIA |
CA2654130A1 (en) | 2006-06-04 | 2007-12-13 | Cellartis Ab | Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells |
EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
WO2007149382A2 (en) | 2006-06-19 | 2007-12-27 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in treating hepatitis |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
US20080081791A1 (en) | 2006-07-06 | 2008-04-03 | Weida Huang | Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi |
CN102532198A (zh) | 2006-07-07 | 2012-07-04 | 吉里德科学公司 | 抗病毒的次膦酸酯化合物 |
MX2009000486A (es) | 2006-07-13 | 2009-01-27 | Achillion Pharmaceuticals Inc | Peptidos de 4-amino-4-oxobutanoilo como inhibidores de replicacion viral. |
WO2008022006A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2666814A1 (en) | 2006-08-21 | 2008-05-29 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
US20080182895A1 (en) | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
US7655419B2 (en) | 2006-08-25 | 2010-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
TW200815384A (en) | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
US9216197B2 (en) | 2006-09-11 | 2015-12-22 | Biomas Ltd. | Topical formulations of tellurium-containing compounds |
BRPI0716744A2 (pt) | 2006-09-14 | 2016-10-04 | Human Genome Sciences Inc | proteínas de fusão de albumina |
WO2008033466A2 (en) | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
EP2083825A4 (en) | 2006-09-26 | 2009-11-04 | Addiction Res Inst Inc | HEPATITIS C TREATMENT COMPOSITIONS AND METHODS OF USING HEPATITIS C TREATMENT COMPOSITIONS |
CA2666098C (en) | 2006-10-10 | 2012-09-25 | Steven D. Axt | Preparation of nucleosides ribofuranosyl pyrimidines |
US7777395B2 (en) | 2006-10-12 | 2010-08-17 | Eastman Kodak Company | Continuous drop emitter with reduced stimulation crosstalk |
JP5268927B2 (ja) | 2006-10-27 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
CA2670260A1 (en) | 2006-11-15 | 2008-05-22 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of flavivirus infections |
WO2008143647A2 (en) | 2006-11-29 | 2008-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating viral infection |
EP2099430A2 (en) | 2006-12-07 | 2009-09-16 | Schering Corporation | Ph sensitive matrix formulation |
RU2336096C1 (ru) | 2006-12-14 | 2008-10-20 | ООО Медицинский центр "Столица" | Способ лечения гепатита с |
RU2345787C2 (ru) | 2006-12-25 | 2009-02-10 | Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" | Способ лечения хронического вирусного гепатита с |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
EA200900969A1 (ru) | 2007-01-08 | 2010-02-26 | Феномикс Корпорейшн | Макроциклические ингибиторы протеазы гепатита с |
WO2008089034A2 (en) | 2007-01-11 | 2008-07-24 | Kemia, Inc. | Cytokine inhibitors |
US7645732B2 (en) | 2007-01-24 | 2010-01-12 | Board Of Regents, The University Of Texas System | Treating hepatitis C virus infection |
DK2118098T3 (da) | 2007-02-01 | 2014-12-08 | Janssen R & D Ireland | Polymorfe former af en makrocyklisk inhibitor af hcv |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
CA2683383C (en) | 2007-02-21 | 2016-01-05 | Allaccem, Incorporated | Bridged polycyclic compound based compositions for the inhibition and amelioration of disease |
US8759353B2 (en) | 2007-02-27 | 2014-06-24 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
WO2008106167A1 (en) | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
MD3477G2 (ro) | 2007-03-21 | 2008-08-31 | Николае БОДРУГ | Metodă de tratament al hepatitei virale cronice C |
EP2308514B1 (en) | 2007-03-23 | 2013-06-05 | to-BBB Holding B.V. | Conjugates for targeted drug delivery across the blood-brain barrier |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
WO2008124384A2 (en) | 2007-04-03 | 2008-10-16 | Aegerion Pharmaceuticals, Inc. | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c |
US20080269205A1 (en) | 2007-04-27 | 2008-10-30 | Ondine International, Ltd. | Methods to prevent vertical transmission of infectious diseases |
EP2155257B1 (en) | 2007-04-27 | 2016-10-05 | Chimerix, Inc. | Methods of reducing nephrotoxicity in subjects administered with nucleoside |
NZ581606A (en) | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
ES2381410T3 (es) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Terapia de combinación paa el tratamiento de infecciones por VHC |
EA200971041A1 (ru) | 2007-05-10 | 2010-08-30 | Интермьюн, Инк. | Новые пептидные ингибиторы репликации вируса гепатита с |
WO2008144072A1 (en) | 2007-05-21 | 2008-11-27 | Vertex Pharmaceuticals Incorporated | Dose forms comprising vx- 950 and their dosage regimen |
RU2348412C1 (ru) | 2007-06-01 | 2009-03-10 | Лариса Леонидовна Попова | Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии |
WO2008154248A1 (en) | 2007-06-06 | 2008-12-18 | Inova Health System | Prognostic chronic hepatitis c biomarkers |
US8178491B2 (en) | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
KR20100056479A (ko) | 2007-07-25 | 2010-05-27 | 바이오렉스 쎄라퓨틱스, 인코포레이티드 | 제어 방출 인터페론 약물 제품 및 이를 사용한 hcv 감염의 치료 |
WO2009015389A2 (en) | 2007-07-26 | 2009-01-29 | Entra Pharmaceuticals Inc. | Skin-patch pump comprising a changing-volume electrochemical actuator |
NZ583652A (en) | 2007-08-03 | 2012-06-29 | Biotron Ltd | Hepatitis c antiviral compositions and methods |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US20110166092A1 (en) | 2007-08-20 | 2011-07-07 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
US8492546B2 (en) | 2007-08-30 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
WO2009033183A2 (en) | 2007-09-08 | 2009-03-12 | University Of Florida Research Foundation | Compounds and methods for treatment of hcv and conditions associated with cd81 binding |
US20090076100A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched gsk625433 |
CA2699280A1 (en) | 2007-09-14 | 2009-03-26 | Schering Corporation | Method of treating hepatitis c patients |
NZ600371A (en) | 2007-09-17 | 2014-07-25 | Abbvie Bahamas Ltd | Uracil or thymine derivative for treating hepatitis c |
SI2203431T1 (sl) * | 2007-09-17 | 2011-12-30 | Abbott Lab | Antiinfekcijski pririmidini in njihove uporabe |
WO2009039246A2 (en) | 2007-09-18 | 2009-03-26 | Stanford University | Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
US20090082414A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched viramidine |
US20090082366A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
BRPI0818178B1 (pt) | 2007-10-03 | 2021-11-23 | Sabell Corporation | Composições herbais para tratar distúrbios hepáticos e método para obter extratos hidroalcoólicos de um órgão de planta selecionado |
US20110270212A1 (en) | 2007-10-05 | 2011-11-03 | Medtronic, Inc. | Pharmacokinetic control for optimized interferon delivery |
EP2214682A2 (en) | 2007-11-05 | 2010-08-11 | Vertex Pharmaceuticals Incorporated | Hcv combination therapies comprising vx-950, peg-ifn and ribavirin |
ES2374117T3 (es) | 2007-11-15 | 2012-02-13 | Madaus Gmbh | Componente de silibinina para el tratamiento de la hepatitis. |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8778877B2 (en) | 2007-12-21 | 2014-07-15 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
AU2008340430B2 (en) | 2007-12-21 | 2013-01-24 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
CN102137676A (zh) | 2007-12-27 | 2011-07-27 | 伊皮芬尼生物科学公司 | 抗病毒化合物 |
EP2268811A1 (en) | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
JP5283106B2 (ja) | 2008-03-14 | 2013-09-04 | 国立大学法人 熊本大学 | C型肝炎ウイルス阻害剤 |
US20100009970A1 (en) | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
US20110045001A1 (en) | 2008-03-28 | 2011-02-24 | Biontex Laboratories Gmbh | Transfection results of non-viral gene delivery systems by influencing of the innate immune system |
WO2009134616A2 (en) | 2008-04-15 | 2009-11-05 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
BRPI0911673A2 (pt) | 2008-04-23 | 2017-12-05 | Vertex Pharma | tratamento de infecções pelo vírus da hepatite c com telaprevir (vx-950) em pacientes não responsivos ao tratamento com interferon-alfa-2a/2b peguilado e ribavirin |
US8008264B2 (en) * | 2008-04-23 | 2011-08-30 | Gilead Sciences, Inc. | 1′-substituted carba-nucleoside analogs for antiviral treatment |
DE102008029669A1 (de) | 2008-05-16 | 2009-11-19 | Schlaak, Jörg Friedrich, Prof. Dr. med. | Neue Therapeutika für die Hepatitis-Therapie |
US20110218512A1 (en) | 2008-06-03 | 2011-09-08 | Aethlon Medical, Inc. | Enhanced antiviral therapy methods and devices |
WO2009149377A1 (en) | 2008-06-05 | 2009-12-10 | Zymogenetics, Llc | Use of pegylated type iii interferons for the treatment of hepatitis c |
KR20110053327A (ko) | 2008-06-10 | 2011-05-20 | 얀센 파마슈티카 엔.브이. | 텔라프레비르 투여 방식 |
CN102123706B (zh) | 2008-06-17 | 2013-08-14 | 米纳斯吉拉斯联合大学 | 血小板活化因子受体在治疗黄病毒科病毒引起的感染中的用途 |
ES2491090T3 (es) | 2008-07-22 | 2014-09-05 | Merck Sharp & Dohme Corp. | Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC |
EP2323681A4 (en) | 2008-07-25 | 2012-11-14 | Univ Colorado | METHODS OF TREATING VIRAL CONDITIONS |
RU2373952C1 (ru) | 2008-07-30 | 2009-11-27 | Юрий Михайлович Амбалов | Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию |
JP2011530519A (ja) | 2008-08-06 | 2011-12-22 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 免疫調節化合物を用いたc型肝炎の治療または予防の方法 |
WO2010015545A1 (en) | 2008-08-07 | 2010-02-11 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
WO2010017432A1 (en) | 2008-08-07 | 2010-02-11 | Schering Corporation | Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
US20100092479A1 (en) | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
WO2010020676A1 (en) | 2008-08-20 | 2010-02-25 | Vib Vzw | The use of topoisomerase type i inhibitors to treat viral infections |
JP2012501345A (ja) | 2008-08-28 | 2012-01-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Hcv遺伝子型の分析 |
WO2010024384A1 (ja) | 2008-08-29 | 2010-03-04 | 国立大学法人大阪大学 | 抗c型肝炎ウイルス組成物 |
MX2011002312A (es) | 2008-09-03 | 2011-04-26 | Vertex Pharma | Co-cristales y formulaciones farmaceuticas que comprenden los mismos. |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
JP5520301B2 (ja) | 2008-09-16 | 2014-06-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 強力なhcv阻害剤である2−チアゾリル−4−キノリニル−オキシ誘導体の結晶形態 |
CN102159245B (zh) | 2008-09-17 | 2013-07-24 | 贝林格尔.英格海姆国际有限公司 | Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合 |
WO2010031832A2 (en) | 2008-09-18 | 2010-03-25 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative |
EP2328656A1 (en) | 2008-09-24 | 2011-06-08 | Vertex Pharmaceuticals Incorporated | Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis " |
US8759010B2 (en) | 2008-09-26 | 2014-06-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Host cell kinases as targets for antiviral therapies against HCV infection |
US9006285B2 (en) | 2008-09-30 | 2015-04-14 | Mochida Pharmaceutical Co., Ltd. | Therapeutic agent for hepatitis C |
EP2341924A4 (en) | 2008-10-02 | 2013-01-23 | David Gladstone Inst | METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
WO2010042683A1 (en) | 2008-10-08 | 2010-04-15 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center | Treating hepatitis c virus infection with over-expression of microrna-196 |
CN102216321A (zh) | 2008-10-15 | 2011-10-12 | 因特蒙公司 | 治疗性抗病毒肽 |
WO2010049438A2 (en) | 2008-10-30 | 2010-05-06 | Innate Pharma | Improved methods of using phosphoantigens for the treatment of diseases |
EP2358439A1 (en) | 2008-11-05 | 2011-08-24 | Vertex Pharmaceuticals Incorporated | Methods for treating hepatitis c virus infection |
SG171771A1 (en) | 2008-11-21 | 2011-07-28 | Boehringer Ingelheim Int | Pharmaceutical composition of a potent hcv inhibitor for oral administration |
ES2527166T3 (es) | 2008-12-10 | 2015-01-21 | Achillion Pharmaceuticals, Inc. | Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral |
EP2356236B1 (en) | 2008-12-11 | 2015-07-29 | Xiangxue Group (Hong Kong) Company Limited | siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION |
CA2745284A1 (en) | 2008-12-18 | 2010-06-24 | F. Hoffmann-La Roche Ag | Biomarkers for hcv treatment response |
CA2748034A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections |
EP2376653A2 (en) | 2008-12-29 | 2011-10-19 | Yissum Research Development Company of The Hebrew University of Jerusalem | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
US8840934B2 (en) | 2009-01-02 | 2014-09-23 | Rainbow Pharmaceutical Sa | Uses of ammonium chloride |
EA201170915A1 (ru) * | 2009-01-09 | 2012-02-28 | Юниверсити Колледж Оф Кардифф Консалтентс Лимитед | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций |
RU2398582C1 (ru) | 2009-01-19 | 2010-09-10 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью |
WO2010093843A2 (en) | 2009-02-12 | 2010-08-19 | Vertex Pharmaceuticals Incorporated | Hcv combination therapies |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
AU2010220324A1 (en) | 2009-03-05 | 2011-09-01 | Ascendis Pharma As | Interferon alpha carrier prodrugs |
WO2010101649A2 (en) | 2009-03-05 | 2010-09-10 | Pablo Gastaminza | Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection |
WO2010122538A1 (en) | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
TR201809600T4 (tr) | 2009-04-25 | 2018-07-23 | Hoffmann La Roche | Farmakokinetiği geliştirmek için yöntemler. |
AP3622A (en) * | 2009-05-13 | 2016-03-02 | Gilead Sciences Inc | Antiviral compounds |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
EA020795B1 (ru) | 2009-05-21 | 2015-01-30 | Мерк Шарп Энд Домэ Корп. | Генетические маркеры, ассоциированные с ответом на интерферон-альфа |
DK2455376T3 (da) * | 2009-06-11 | 2015-03-02 | Abbvie Bahamas Ltd | Heterocykliske forbindelser som inhibitorer af hepatitis C-virus (HCV) |
US20100324060A1 (en) | 2009-06-23 | 2010-12-23 | Gilead Sciences, Inc. | Pharmaceutical compositions useful for treating hcv |
WO2010151487A1 (en) | 2009-06-23 | 2010-12-29 | Gilead Sciences, Inc. | Combination of telaprevir with 5- ({6- [2,4-bis (trifluoromethyl) phenyl] pyridazin-3 -yl)methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c]pyridine for the treatment of hcv |
TW201111381A (en) | 2009-06-23 | 2011-04-01 | Gilead Sciences Inc | Pharmaceutical combinations useful for treating HCV |
EP3895706A1 (en) | 2009-06-26 | 2021-10-20 | Romark Laboratories, L.C. | Thiazolinide compounds for treating non-influenza viral infections |
CA2767692C (en) | 2009-07-07 | 2017-03-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
RU2400229C1 (ru) | 2009-07-13 | 2010-09-27 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а |
EP2467144A1 (en) | 2009-07-24 | 2012-06-27 | ViroLogik GmbH | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
KR20120040725A (ko) | 2009-07-31 | 2012-04-27 | 위니버르시티 오브 베른 | Hcv 감염 환자에서 c형 간염 결과를 진단 또는 예측하기 위한 방법 |
WO2011025849A1 (en) | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis c virus |
US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
TW201116540A (en) | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
US8729058B2 (en) | 2009-10-27 | 2014-05-20 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
US9174988B2 (en) | 2009-10-27 | 2015-11-03 | Trustees Of Boston University | Small molecule inhibitors of hepatitis C virus |
BR112012010110A2 (pt) | 2009-10-30 | 2019-09-24 | Boehringer Ingelheim Int | regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina |
JP2013511259A (ja) | 2009-11-09 | 2013-04-04 | メルク・シャープ・アンド・ドーム・コーポレーション | リバビリン誘発性貧血と関連しているマーカー |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
EP2512480A4 (en) * | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US20130029904A1 (en) | 2009-12-18 | 2013-01-31 | Boehringer Ingelheim International Gmbh | Hcv combination therapy |
US20110150836A1 (en) | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
CN102905763B (zh) | 2009-12-23 | 2015-06-17 | 诺华股份有限公司 | 脂质、脂质组合物和使用它们的方法 |
RU2424794C1 (ru) | 2009-12-30 | 2011-07-27 | Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) | Способ лечения врожденного гепатита с у детей первого года жизни |
CN102843909A (zh) * | 2010-01-25 | 2012-12-26 | 埃南塔制药公司 | 丙型肝炎病毒抑制剂 |
TW201130502A (en) | 2010-01-29 | 2011-09-16 | Vertex Pharma | Therapies for treating hepatitis C virus infection |
MY156888A (en) | 2010-03-10 | 2016-04-15 | Abbvie Bahamas Ltd | Solid Compositions |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
SG184323A1 (en) * | 2010-03-31 | 2012-11-29 | Gilead Pharmasett Llc | Stereoselective synthesis of phosphorus containing actives |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
WO2011156757A1 (en) | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Combination of anti-hcv compounds with ribavirin for the treatment of hcv |
CA2745102A1 (en) | 2010-06-29 | 2011-12-29 | Medicorp Institute Of Canada | Pharmaceutical composition and method of use to improve organ function |
RU2429877C1 (ru) | 2010-06-30 | 2011-09-27 | Общество с ограниченной ответственностью "ИНГИЛС" | Способ лечения хронического вирусного гепатита с |
WO2012009503A1 (en) | 2010-07-14 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | Palatable pharmaceutical composition comprising vx-950 |
CA2805760A1 (en) | 2010-07-30 | 2012-02-02 | Merck Sharp & Dohme Corp. | Inhibition of cyp3a drug metabolism |
US20120196272A1 (en) | 2010-08-05 | 2012-08-02 | Roche Molecular Systems, Inc. | Prediction of HCV Viral Kinetics in Interferon-Free Treatment |
US20120196794A1 (en) | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
KR20130110170A (ko) | 2010-09-22 | 2013-10-08 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오타이드 유사체 |
WO2012050850A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases |
EA201300421A1 (ru) | 2010-09-30 | 2013-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Комбинированная терапия для лечения инфекции hcv |
EP2632261B1 (en) * | 2010-10-26 | 2016-07-13 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
US20120107278A1 (en) | 2010-10-29 | 2012-05-03 | Pharmasset, Inc. | Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype |
JP5891241B2 (ja) | 2010-12-20 | 2016-03-22 | ギリアード サイエンシーズ, インコーポレイテッド | Hcvを処置するための組合せ |
CA2832818A1 (en) | 2011-04-06 | 2012-10-11 | The Trustees Of Princeton University | Anti-viral combination therapy |
WO2012175733A1 (en) | 2011-06-23 | 2012-12-27 | Santaris Pharma A/S | Hcv combination therapy |
JP2014520772A (ja) | 2011-06-30 | 2014-08-25 | ステラ・アンパルトセルスカブ | Hcv併用療法 |
JP2014523429A (ja) | 2011-06-30 | 2014-09-11 | ステラ・アンパルトセルスカブ | Hcv併用療法 |
WO2013024158A1 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection |
WO2013025975A1 (en) | 2011-08-17 | 2013-02-21 | Glaxosmithkline Llc | Combination treatments for hepatitis c |
WO2013024155A1 (en) | 2011-08-17 | 2013-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
EP2747569A4 (en) | 2011-08-24 | 2015-07-08 | Glaxosmithkline Llc | COMBINATION TREATMENTS FOR HEPATITIS C |
MX354958B (es) * | 2011-09-16 | 2018-03-27 | Gilead Pharmasset Llc | Metodos para el tratamiento de vhc. |
UY34401A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
US8492386B2 (en) * | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
US8466159B2 (en) * | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
EP2773342A4 (en) | 2011-10-31 | 2015-08-26 | Merck Sharp & Dohme | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES |
US20130137084A1 (en) | 2011-11-28 | 2013-05-30 | Roche Molecular Systems, Inc. | Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses |
WO2013096680A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
-
2012
- 2012-10-19 UY UY0001034401A patent/UY34401A/es not_active Application Discontinuation
- 2012-10-19 WO PCT/US2012/061085 patent/WO2013059638A1/en active Application Filing
- 2012-10-19 MX MX2014004729A patent/MX2014004729A/es active IP Right Grant
- 2012-10-19 JP JP2014537304A patent/JP5677646B2/ja not_active Expired - Fee Related
- 2012-10-19 DK DK12189195.6T patent/DK2583680T1/da unknown
- 2012-10-19 PT PT107925A patent/PT107925A/pt not_active IP Right Cessation
- 2012-10-19 TW TW101138779A patent/TWI532485B/zh not_active IP Right Cessation
- 2012-10-19 AU AU2013201532A patent/AU2013201532B2/en not_active Expired - Fee Related
- 2012-10-19 CH CH00096/14A patent/CH707030B1/de not_active IP Right Cessation
- 2012-10-19 PT PT107924A patent/PT107924A/pt not_active IP Right Cessation
- 2012-10-19 DE DE112012002813.9T patent/DE112012002813T5/de not_active Withdrawn
- 2012-10-19 BR BR112014005617A patent/BR112014005617A2/pt unknown
- 2012-10-19 CA CA2811250A patent/CA2811250C/en not_active Expired - Fee Related
- 2012-10-19 DE DE202012013117.6U patent/DE202012013117U1/de not_active Expired - Lifetime
- 2012-10-19 DE DE202012012955.4U patent/DE202012012955U1/de not_active Expired - Lifetime
- 2012-10-19 EP EP12189195.6A patent/EP2583680A3/en not_active Withdrawn
- 2012-10-19 GB GB1418014.5A patent/GB2515942A/en not_active Withdrawn
- 2012-10-19 SG SG2014011670A patent/SG2014011670A/en unknown
- 2012-10-19 CN CN201280048057.8A patent/CN104023726A/zh active Pending
- 2012-10-19 TW TW104130527A patent/TW201600087A/zh unknown
- 2012-10-19 US US13/656,012 patent/US8809265B2/en active Active
- 2012-10-19 ES ES12189195.6T patent/ES2527544T1/es active Pending
- 2012-10-19 DE DE202012012954.6U patent/DE202012012954U1/de not_active Expired - Lifetime
- 2012-10-19 DE DE112012006327.9T patent/DE112012006327A5/de not_active Withdrawn
- 2012-10-19 AR ARP120103919A patent/AR088408A1/es unknown
- 2012-10-19 CN CN201410540177.0A patent/CN104436197A/zh active Pending
- 2012-10-19 EA EA201490836A patent/EA201490836A1/ru unknown
- 2012-10-19 SE SE1450131A patent/SE1450131A1/sv not_active Application Discontinuation
- 2012-10-19 GB GB1400674.6A patent/GB2506085A/en not_active Withdrawn
- 2012-10-19 DE DE112012003457.0T patent/DE112012003457T5/de not_active Withdrawn
- 2012-10-19 SE SE1450020A patent/SE1450020A1/sv not_active Application Discontinuation
-
2014
- 2014-02-06 IL IL230862A patent/IL230862A0/en unknown
- 2014-03-28 CL CL2014000778A patent/CL2014000778A1/es unknown
- 2014-04-08 DO DO2014000067A patent/DOP2014000067A/es unknown
- 2014-05-15 GB GBGB1408664.9A patent/GB201408664D0/en not_active Ceased
- 2014-07-14 US US14/330,495 patent/US20140323395A1/en not_active Abandoned
- 2014-08-28 ZA ZA2014/06352A patent/ZA201406352B/en unknown
- 2014-10-09 JP JP2014208264A patent/JP2015071599A/ja active Pending
- 2014-12-22 PH PH12014502847A patent/PH12014502847A1/en unknown
-
2015
- 2015-01-09 HK HK15100267.9A patent/HK1199817A1/xx unknown
- 2015-01-14 HK HK15100422.1A patent/HK1200022A1/xx unknown
- 2015-10-05 CL CL2015002968A patent/CL2015002968A1/es unknown
-
2016
- 2016-01-20 GB GBGB1601076.1A patent/GB201601076D0/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2583680T1 (da) | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV | |
DK2583677T1 (da) | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon | |
JP2014530874A5 (da) | ||
DE12189198T1 (de) | Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon. | |
DE12189195T1 (de) | Einzel- (PSI-7977) oder Kombinationsbehandlung in der Verwendung zur Behandlung von HCV | |
NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
HRP20171898T1 (hr) | Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika | |
JP2016513703A5 (da) | ||
JP2013518124A5 (da) | ||
RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
JP2013529627A5 (da) | ||
Lawitz et al. | Interferon-and Ribavirin-free Regimen of ABT-450/r+ ABT-267 in HCV Genotype 1b-infected Treatment-naïve Patients and Prior Null Responders: 75 | |
MX2018000240A (es) | Metodos para tratar el vhc. | |
NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
JP2016538306A5 (da) | ||
Wyles et al. | Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/MK-8408 in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) | |
BR112017000052A2 (pt) | solução cardioplégica de uso geral (variantes) | |
Puoti et al. | Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs | |
Alqahtani et al. | Safety of Ledipasvir/Sofosbuvir with and without Rib-avirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials: 1944 | |
WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin | |
Poordad et al. | Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 with SVR24 After Treatment with ABT-450/r, ABT-267, ABT-333+ Ribavirin in Patients with Chronic HCV Genotype 1 Infection in the AVIATOR Study: 1089 | |
Pearlman et al. | Hepatitis C virus (HCV) genotype 1 (G1) infection with low viral load (LVL) and rapid virologic response (RVR) to peginterferon and ribavirin (PEG/RBV) can be treated without a protease inhibitor (PI), irrespective of IL-28B status or patient ethnicity: 151 | |
Nettles et al. | BMS-790052, A FIRST-IN CLASS POTENT HEPATITIS C VIRUS NS5A INHIBITOR, DEMONSTRATES MULTIPLEDOSE PROOF-OF-CONCEPT IN SUBJECTS WITH CHRONIC GT1 HCV INFECTION: 1881 | |
JP2017514834A5 (da) |